Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.50 |
| ▸ | TACR1 | P25103 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24970327 | 0.84 | SLC6A2 (0.54) | SLC6A4SLC6A2SLC6A3TACR1MEN1 | |
| SCHEMBL20567196 | 0.84 | SLC6A2 (0.54) | SLC6A4SLC6A2SLC6A3TACR1MEN1 | |
| SCHEMBL13541680 | 0.83 | SLC6A2 (0.65) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL19711166 | 0.74 | SLC6A2 (0.44) | SLC6A4SLC6A2SLC6A3HRH3GRIN2B | |
| SCHEMBL18716730 | 0.73 | KDM4E (0.60) | SLC6A4SLC6A2SLC6A3HRH3GRIN2B | |
| SCHEMBL20920392 | 0.73 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3TACR1MEN1 | |
| SCHEMBL25487686 | 0.72 | SLC6A2 (0.34) | SLC6A4SLC6A2 | |
| SCHEMBL25487553 | 0.72 | AGTR2 (0.48) | SLC6A4SLC6A2SLC6A3TACR1HRH3 | |
| SCHEMBL13541681 | 0.71 | SLC6A2 (0.65) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL707011 | 0.71 | SLC6A2 (0.52) | SLC6A4SLC6A2SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | SLC6A4 4614/4885SLC6A2 4712/4885SLC6A3 4414/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | SLC6A4 4668/4885SLC6A2 4766/4885SLC6A3 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.